SAB Biotherapeutics Will Sell $130 Million Shares of Preferred Stock to Advance Diabetes Treatment
By Karen E. Roman SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company,...
By Karen E. Roman SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company,...
By Daniella Parra ProSomnus, Inc. (NASDAQ: OSA) said it raised $10 million in a convertible...
Healthcare Edge hosted a fireside chat from the floor of the New York Stock Exchange...
By Daniella Parra ProSomnus, Inc. (NASDAQ: OSA) is set to feature its precision sleep apnea...
By Daniella Parra Sparrow Pharmaceuticals expanded its Phase 2 clinical trial for SPI-62 in combination...
By Daniella Parra Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company specializing in advanced...
By Daniella Parra Plus Therapeutics, Inc. (Nasdaq: PSTV) has expanded its partnership with Biocept with...
By Daniella Parra Eterna Therapeutics Inc. (Nasdaq: ERNA) is partnering with Lineage Cell Therapeutics, Inc....
By Karen E. Roman Octave Bioscience, Inc., a company offering treatment for multiple sclerosis and...
By Karen E. Roman Plus Therapeutics, Inc. (Nasdaq: PSTV) announced treatment of the first patient in Part...